Navigation Links
TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
Date:9/25/2008

y authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's product development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical trials will be reported within the anticipated timeframe, that tezampanel or NGX426 will successfully treat migraine and/or other indications for which they are developed, that the End of Phase II meeting will be held in the anticipated time frame, that NGX267 will successfully treat xerostomia secondary to Sjogren's syndrome, that TorreyPines will be able to complete the necessary development work and receive regulatory approval for tezampanel, NGX426 or NGX267 or that TorreyPines will be able to reach agreement with a partner for any of the product candidates or programs on terms that are acceptable to TorreyPines. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2007 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is likely to change and speak only as of the date hereof.

Company Contact:

Craig Johnson

TorreyPines Therapeutics, Inc.

858-623-5665, x158

cjohnson@torreypinestherapeutics.com

Media Contact:

David Schull

Russo Partners, LLC

212-845-4271

david.schull@russopartners.com

Investor Contact:

Rhonda Chiger

Rx Communications

917-322-2569

rchiger@RxIR.com


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. TorreyPines Therapeutics Reports Third Quarter 2007 Results
7. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
8. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
11. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014 Human Longevity, ... therapeutic company focused on extending the healthy, high performance ... Franz Och , Ph.D., an expert in machine learning ... Och comes to HLI from Google where he was ... He will report directly to HLI Co-Founder and CEO, ...
(Date:7/29/2014)... (July 29, 2014) Tough, ultralight foam of ... shape through a chemical process invented at Rice University. ... looks like a nanoscale building, with floors and walls ... pair of two-dimensional materials: floors and walls of graphene ... nitride platelets. , The researchers say the foam ...
(Date:7/29/2014)... , July 29, 2014  The Society ... new and updated program for the 9 th ... 12, 2014 in Amelia Island , Florida.  ... and investigators remains unchanged, however, the topics and ... and networking opportunity among all stakeholders with a ...
(Date:7/29/2014)... Second generation biofuels are a viable solution to the dilemma ... gas is very cheap, this is affecting the biofuels market ... they could be in comparison to natural gas. This, ... difficult for renewable energy developers to get the economics to ... reasons, certain companies have shifted their focused within renewable energy. ...
Breaking Biology Technology:Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3Tough foam from tiny sheets 2TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 2TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 3Renewable Waste Intelligence: Could Renewable Chemicals Be the Future for the Renewable Energy Industry? 2
... NORWOOD, Mass., Aug. 24 Advanced Instruments has introduced a ... experience when purchasing osmometers, cryoscopes, and microbiological laboratory instruments. The ... es.com , was developed from the perspective of ... application information, scientific materials, and technical support. , , ...
... SAN DIEGO, Aug. 24 Orexigen((R)) Therapeutics, Inc. (Nasdaq: ... joined the Company as Chief Commercial Officer. Mr. Booth ... to Orexigen. Most recently he served as President of ... commercial, medical and scientific affairs, business development and all support ...
... August 24 Foamix Ltd., a leading,developer of topical ... been awarded US Patent #7575739 pertaining to its foam,technology. ... of heat and chemical burns, wounds, bacterial, fungal and ... the Company,s CEO stated, "The novelty of our foam,technology ...
Cached Biology Technology:Advanced Instruments Introduces Next-Generation Web Site 2Orexigen(R) Therapeutics Appoints Mark Booth Chief Commercial Officer 2Foamix Receives US Patent on Novel Foam Technology 2
(Date:7/29/2014)... have been plaguing the Northern Territories in Canada and ... in the U.S. continue on. NASA,s Aqua satellite ... Spectroradiometer, MODIS, instrument on July 26, 2014. Actively burning ... red. Copious amount of smoke are drifting northward in ... residents of Yellowknife. Fire has caused power outages ...
(Date:7/29/2014)... easier method to create DNAprotein conjugates. The method ... diseases. , DNA linked to proteins including ... be used in diagnostic techniques, nanotechnology and other ... DNA can be used for purposes such ... material. The method also provides easier access to ...
(Date:7/29/2014)... from scientists at the University of Kent has shown ... are regulated a breakthrough that could have a ... from Kent,s School of Biosciences uncovered the mechanism whereby ... known as actin filaments are ,fine-tuned, to ... filaments appear to completely stable, providing a framework for ...
Breaking Biology News(10 mins):New method provides researchers with efficient tool for tagging proteins 2
... This press release is available in French . ... people are not slower but rather wiser than young brains, ... performance, according research undertaken at the University Geriatrics Institute of ... the Univeristy of Montreal. "The older brain has experience and ...
... Society of Interventional Radiology Foundation,s Discovery Campaign, which ... medicine into new areas of discovery, announced a ... manufacturer of medical devices, pharmaceuticals and medical supplies, ... is a "Visionary" level supporter. "Collaboration ...
... one way that old-fashioned newsprint beats the Internet. Tulane ... "TU-103," that can use paper to produce butanol, a ... They are currently experimenting with old editions of the ... success., ,TU-103 is the first bacterial strain from nature ...
Cached Biology News:Clinical study shows young brains lack the wisdom of their elders 2Cars could run on recycled newspaper, Tulane scientists say 2
...
... Fully adjustable mixing angle, Variable speed, Digital ... a number of different sized tubes, Spillage ... cultures, keeping biological samples in suspension and ... be used in incubators up to 60C ...
... The DNA Engine Opticon 2 real-time PCR ... LEDs for fluorescence excitation (470-505 nm) and ... nm, 540-700 nm). The Opticon 2 system ... cycler, which includes a thermal gradient feature. ...
... Multicolor capability allows detection of SYBR ... channel, and a range of fluorophores in ... VIC, and TAMRA for a multitude ... discrimination. DNA Engine thermal cycler offers precision ...
Biology Products: